More effective positioning of capecitabine for advanced and metastatic breast cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 4, 2010, Pages 649-653

  Tsuyuki, Shiqeru ^a   Kawaguchi Sakita, Nobuko ^a,b   Tsubota, Yu ^a   Ukikusa, Minoru ^a   Kohno, Yukihiro ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Capecitabine; Metastatic breast cancer

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PRIMARY TUMOR; SKIN METASTASIS; SOFT TISSUE INJURY; SOFT TISSUE METASTASIS; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 79960818077     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Kono A, Hara Y, Sugata S, et al: Activation of 5′-deoxy-5- fluorouridine by thymidine Phosphorylase in human tumors. Chem Pharm Bull 31(1): 175-178, 1983. (Pubitemid 13122231)
2. O'Shaughnessy JA, Blum J, Moiseyenko V, et al: Randomized, openlabel, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12: 1247-1254, 2001. (Pubitemid 32994752)
3. Bajetta E, Procopio G, Celio L, et al: Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23: 2155-2161, 2005. (Pubitemid 46218707)
4. Talbot DC, Moiseyenko V, Van Belle S, et al: Randomized, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86: 1367-1372, 2002. (Pubitemid 34548055)
5. Osako T, Ito Y, Ushijima M, et al: Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 63: 865-871, 2009.
6. Andreetta C, Puppin C, Minisini A, et al: Thymidine Phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol 20: 265-271, 2009.
7. Noguchi S, Koyama H, Uchino J, et al: Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. J Clin Oncol 23: 2172-2184, 2005. (Pubitemid 46218709)
8. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002. (Pubitemid 34651510)
9. Welt A, von Minckwitz G, Oberhoff C, et al: Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16: 64-69, 2005.
10. Tanaka M, Tamura K, Anan K, et al: Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: Phase II study. Cancer Res 69(suppl 2): 6119 (abstr), 2009.
11. Moritimer JE, Lauman MK, Tan B, et al: Pyridoxine treatment and prevention of hand-foot syndrome in patients receiving capecitabine. J Oncol Pharm Practice 9: 161-166, 2003. (Pubitemid 37461547)